GHK-Cu Side Effects: What the Published Research Shows

GHK is a naturally occurring tripeptide of three amino acids, glycyl-histidyl-lysine, with a strong binding affinity for copper(II) ions; bound together, the complex is written GHK-Cu. A 2018 review in the International Journal of Molecular Sciences catalogued a wide range of proposed biological actions for the peptide across cell-based and animal research, from tissue-repair and blood-vessel signalling to antioxidant and DNA-repair gene expression.^[1]

That catalogue is a mechanism review, not a safety trial, and cataloguing a molecule's proposed actions is a different exercise from establishing what happens when people are exposed to it. It is background for why the same peptide turns up in both skincare formulations and injectable research contexts, and why its bound copper is the recurring question in both settings.^[1]

The rest of this article works through that question route by route: what topical human studies report, what laboratory work says about copper itself, and what remains unverified for injected GHK-Cu.

The clearest published human data on topical GHK-Cu comes from a randomised trial in people recovering from CO2 laser skin resurfacing — skin that is freshly injured and unusually reactive, which makes it a demanding tolerability test rather than a gentle one. Thirteen patients completed the protocol, split between a post-procedure skin-care regimen that included a GHK-Cu copper-tripeptide product and one that did not, with outcomes assessed at 12 weeks.^[2]

Computer analysis and blinded evaluators found no statistically significant difference between the two groups in how quickly post-laser redness resolved, and both groups showed comparable improvement in wrinkles and overall skin quality. The published results describe no additional adverse reaction tied to the GHK-Cu regimen specifically; the one measured difference between groups was that patients using the GHK-Cu products reported significantly higher satisfaction, despite the objective measurements coming out even.^[2]

Read narrowly, that is a tolerability signal from a single trial of one product format, on patients whose skin was already compromised by a procedure — not a broad safety verdict for every GHK-Cu cream or serum sold as a cosmetic, and not evidence about any other route of exposure.^[2]

Because GHK-Cu carries a bound copper ion, a reasonable question is whether the copper itself, rather than the peptide backbone, is what could irritate skin. A 2016 laboratory study tested GHK-Cu alongside two ionic copper compounds, copper chloride and copper acetate, on human keratinocyte cells, measuring cell viability and the expression of several skin-irritation biomarkers, including IL-1α, IL-8, HSPA1A and FOSL1.^[3]

GHK-Cu was not cytotoxic at the concentrations tested and did not significantly change expression of those irritation markers. The two ionic copper salts raised several of the same markers at higher concentrations without an accompanying loss of cell viability — a pattern the study's authors read as showing that copper bound inside the GHK-Cu complex behaves differently on skin cells than free copper ions, with a lower irritation potential in this model.^[3]

That is cell-culture evidence, not a human trial, so it answers a narrower question than "is GHK-Cu safe": specifically, whether copper bound in this complex behaves like free ionic copper on skin cells at the concentrations tested. It says nothing about systemic exposure, and nothing about injected GHK-Cu, covered next.^[3]

Peptyds' GHK-Cu ships as a lyophilised powder supplied for laboratory research only — not the topical serum format the studies above tested. For the injectable route, the evidence gap is explicit in the FDA's own review of nominated compounding substances: it states that compounded injectable drugs containing GHK-Cu may pose an immunogenicity risk tied to aggregation and peptide-related impurities, and that human safety data remain limited.^[4]

As of that page's most recent update, 22 April 2026, the GHK-Cu injectable note sits under substances "nominated but withdrawn" rather than an active significant-safety-risk listing: the concern was raised during FDA's review of the nomination, and the nomination itself was subsequently withdrawn. No published controlled human trial establishing the safety of injected GHK-Cu was identified for this article, in either direction.^[4]

That leaves a real evidence gap rather than a settled answer, as of September 2026, and it is the kind of status that can still move. The topical tolerability data above and the FDA's compounding note describe two different things: one peptide, tested and regulated very differently depending on how it reaches the body.

Peptyds lists GHK-Cu as a lyophilised vial for reconstitution, supplied for laboratory research only. That is not the topical serum format the tolerability studies above describe, and the published safety record does not transfer cleanly between the two: a different formulation is also a different evidence base, tested through a different route, under different regulatory attention.

Peptyds' own comparison of GHK-Cu and BPC-157 for skin research covers that topical-versus-systemic distinction in more depth, including why a cosmetic "GHK-Cu serum" and a reconstituted research vial are not interchangeable evidence bases despite sharing a molecule name. For how GHK-Cu's evidence record compares with other research peptides more broadly, Peptyds' wider safety overview covers common side effects, long-term data, and what remains unknown across the catalogue.

None of the research summarised here is a promise about what any specific product does in any specific person. It is the published record, reported as published, so the gap between cosmetic-ingredient evidence and a laboratory research compound stays visible rather than blurred.